|
1
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Michan S and Sinclair D: Sirtuins in
mammals: insights into their biological function. Biochem J.
404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaziri H, Dessain SK, Ng Eaton E, et al:
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell.
107:149–159. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dai JM, Wang ZY, Sun DC, Lin RX and Wang
SQ: SIRT1 interacts with p73 and suppresses p73-dependent
transcriptional activity. J Cell Physiol. 210:161–166. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wong S and Weber JD: Deacetylation of the
retinoblastoma tumour suppressor protein by SIRT1. Biochem J.
407:451–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huffman DM, Grizzle WE, Bamman MM, et al:
SIRT1 is significantly elevated in mouse and human prostate cancer.
Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jung-Hynes B and Ahmad N: Role of p53 in
the anti-proliferative effects of Sirt1 inhibition in prostate
cancer cells. Cell Cycle. 8:1478–1483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuzmichev A, Margueron R, Vaquero A, et
al: Composition and histone substrates of polycomb repressive group
complexes change during cellular differentiation. Proc Natl Acad
Sci USA. 102:1859–1864. 2005. View Article : Google Scholar
|
|
9
|
Zhang Y, Zhang M, Dong H, et al:
Deacetylation of cortactin by SIRT1 promotes cell migration.
Oncogene. 28:445–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stünkel W, Peh BK, Tan YC, et al: Function
of the SIRT1 protein deacetylase in cancer. Biotechnol J.
2:1360–1368. 2007.
|
|
11
|
Kabra N, Li Z, Chen L, et al: SirT1 is an
inhibitor of proliferation and tumor formation in colon cancer. J
Biol Chem. 284:18210–18217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu G, Yuan X, Zeng Z, et al: Analysis of
gene expression and chemoresistance of CD133+ cancer
stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jang KY, Hwang SH, Kwon KS, et al: SIRT1
expression is associated with poor prognosis of diffuse large
B-cell lymphoma. Am J Surg Pathol. 32:1523–1531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bradbury CA, Khanim FL, Hayden R, et al:
Histone deacetylases in acute myeloid leukaemia show a distinctive
pattern of expression that changes selectively in response to
deacetylase inhibitors. Leukemia. 19:1751–1759. 2005. View Article : Google Scholar
|
|
15
|
Yuan Z, Zhang X, Sengupta N, Lane WS and
Seto E: SIRT1 regulates the function of the Nijmegen breakage
syndrome protein. Mol Cell. 27:149–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chu F, Chou PM, Zheng X, Mirkin BL and
Rebbaa A: Control of multidrug resistance gene mdr1 and cancer
resistance to chemotherapy by the longevity gene sirt1. Cancer Res.
65:10183–10187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng HL, Mostoslavsky R, Saito S, et al:
Developmental defects and p53 hyperacetylation in Sir2 homolog
(SIRT1)-deficient mice. Proc Natl Acad Sci USA. 100:10794–10799.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsushita N, Takami Y, Kimura M, et al:
Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and
cisplatin-induced cell death in vertebrate cells. Genes Cells.
10:321–332. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kojima K, Ohhashi R, Fujita Y, et al: A
role for SIRT1 in cell growth and chemoresistance in prostate
cancer PC3 and DU145 cells. Biochem Biophys Res Commun.
373:423–428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan J, Minter-Dykhouse K and Lou Z: A
c-Myc-SIRT1 feedback loop regulates cell growth and transformation.
J Cell Biol. 185:203–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Firestein R, Blander G, Michan S, et al:
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon
cancer growth. PLoS One. 3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chua KF, Mostoslavsky R, Lombard DB, et
al: Mammalian SIRT1 limits replicative life span in response to
chronic genotoxic stress. Cell Metab. 2:67–76. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang RH, Sengupta K, Li C, et al: Impaired
DNA damage response, genome instability, and tumorigenesis in SIRT1
mutant mice. Cancer Cell. 14:312–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lim CS: SIRT1: tumor promoter or tumor
suppressor? Med Hypotheses. 67:341–344. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li K and Luo J: The role of SIRT1 in
tumorigenesis. N Am J Med Sci. 4:104–106. 2011. View Article : Google Scholar
|
|
26
|
Tavassoli FA and Devilee P; World Health
Organization Classification of Tumours. Pathology and Genetics of
Tumours of the Breast and Female Genital Organs. IARC Press; Lyon:
2003
|
|
27
|
Sung JY, Kim R, Kim JE and Lee J: Balance
between SIRT1 and DBC1 expression is lost in breast cancer. Cancer
Sci. 101:1738–1744. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heltweg B, Gatbonton T, Schuler AD, et al:
Antitumor activity of a small-molecule inhibitor of human silent
information regulator 2 enzymes. Cancer Res. 66:4368–4377. 2006.
View Article : Google Scholar
|
|
29
|
Ota H, Tokunaga E, Chang K, et al: Sirt1
inhibitor, Sirtinol, induces senescence-like growth arrest with
attenuated Ras-MAPK signaling in human cancer cells. Oncogene.
25:176–185. 2006.PubMed/NCBI
|
|
30
|
Ford J, Jiang M and Milner J:
Cancer-specific functions of SIRT1 enable human epithelial cancer
cell growth and survival. Cancer Res. 65:10457–10463. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reed JC: Bcl-2-family proteins and
hematologic malignancies: history and future prospects. Blood.
111:3322–3330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hockenbery DM: Targeting mitochondria for
cancer therapy. Environ Mol Mutagen. 51:476–489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Amundson SA, Myers TG, Scudiero D, Kitada
S, Reed JC and Fornace AJ Jr: An informatics approach identifying
markers of chemosensitivity in human cancer cell lines. Cancer Res.
60:6101–6110. 2000.PubMed/NCBI
|
|
34
|
Zhang M, Guo R, Zhai Y and Yang D: LIGHT
sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer
cells leading to down-regulation of anti-apoptosis Bcl-2 family
members. Cancer Lett. 195:201–210. 2003. View Article : Google Scholar
|
|
35
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
